CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors
CD93 blockade normalizes tumor vasculature leading to improved effector T-cell infiltration and function in solid cancers. Our study advocates the application of CD93 blockade for ACT in solid cancers.
Authors
- Yi Sun (ORCID: https://orcid.org/0000-0002-0194-2476)
- Yujie Guo (ORCID: https://orcid.org/0000-0001-9497-2836)
- Yuwen Zhu (ORCID: https://orcid.org/0000-0003-1434-6590)
- Eduardo Dávila (ORCID: https://orcid.org/0000-0001-9738-4167)
- Elliott J. Yee (ORCID: https://orcid.org/0009-0006-6807-2168)
- Richard D. Schulick (ORCID: https://orcid.org/0000-0001-7360-7338)
- Yuki Fujiwara (ORCID: https://orcid.org/0000-0002-8801-4284)
- Zhiwei Sun (ORCID: https://orcid.org/0000-0002-3898-029X)
- Kaitlyn Dickinson
- Junyi Hu
Institutions
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-010554
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- National Jewish Health
- National Institutes of Health
- Cancer Center, University of Colorado
- National Cancer Institute